Abstract
The rational administration of any drug to a patient requires some knowledge of the anticipated efficacy and toxicity for a particular dose of that drug. When an understanding of how an individual patient will absorb and eliminate a drug is coupled together with knowledge of the pharmacologic effects of a given amount of the drug, a particular dose can be selected that will result in clinical efficacy and minimal toxicity. Such considerations have been defined adequately for many classical drugs; however, this approach has not been used as yet for the new peptide and protein therapeutic agents. Thus, today we are interested in gaining an understanding of the pharmacokinetics and pharmacodynamics of peptide and protein drugs. Pharmacokinetics may be simply described as the mathematical relationship that exists between the dose of a drug and the measureable concentration in a readily accessible site in the body (e.g., plasma or blood). Pharmacodynamics extends this relationship to a correlation between measured concentrations of drug and the pharmacologic effect. As a simple description, pharmacokinetics describes what the body does to the drug, as opposed to pharmacodynamics which describes what the drug does to the body. There are two major uses for pharmacokinetics. First, as a tool in therapeutics to help the clinician choose the right dosage regimen for a particular drug in a specific patient. Second, pharmacokinetics may be used as a tool in defining drug disposition. As indicated above, up to the present time the therapeutic use of pharmacokinetics for proteins and peptide drug compounds has not been realized. However, regulatory agencies do require information concerning drug disposition which can be best described using pharmacokinetic principles, i.e., the use of pharmacokinetics as a tool in defining drug disposition.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Benet, L.Z., 1984, Pharmacokinetic parameters; which are necessary to define a drug substance? Eur. J. Resp. Dis., 65(Suppl 134):45–61.
Binder, C., Lauritzen, T., Faber, O. and Pramming, S., 1984, Insulin pharmacokinetics, Diabetes Care, 7: 188–199.
Bocci, V., 1985, Distribution, catabolism and pharmacokinetics of interferons, in: “Interferon, Vol.4,” Finter, N.B. and Oldham, R., eds., Elsevier, Amsterdam.
Foon, K.A. Sherwin, S.A., Abrams, P.G., Stevenson, H.C., Holmes, P., Maluish, A.E., Oldham, R.K. and Herberman, R.B., 1985, A phase I trial of recombinant gamma interferon in patients with cancer, Cancer Immunol. Immunother., 20: 193–197.
Hotchkiss, A., Ross, M., Refino, C., Chen, S., Fuller, G. and Baughman, R.A., 1987, Circulation, submitted for publication.
Korninger, C., Stassen, J.M., and Collen, D., 1981, Turnover of human extrinsic (tissue-type) plasminogen activator, Thromb. Haemostas. (Stuttgart), 46: 658–661.
Kurzrock, R., Rosenblum, M.G., Sherwin, S.A., Rios, A. Talpaz, M. Quesada, J.R., and Gutterman, J.U., 1985, Pharmacokinetics, single-dose tolerance, and biological activity of recombinant α-interferon in cancer patinets, Cancer Res., 45: 2866–2872.
Nestor, J.J., Ho, T.L., Tahilrami, R., McRae, G.I., and Vickery, B.H., 1984, Long acting LH-RH agonists and antagonists, Int. Cong. Ser.-Excerpta Med., 656: 24–35.
Owens, D.R., Hayes, T.M., Alberti, K.G.M.M., Jones, M.K., Heding, L.G., Home, P.D., and Burrin, J.M., 1981, Comparative study of subcutaneous, intramuscular, and intravenous administration of human insulin, Lancet, 1: 118–122.
Rijken, D.C., Hoylaerts, M., and Collen, D., 1982, Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator, J. Biol. Chem., 257:2920–2925.
Vadhan-Raj, S., Al-Katib, A., Bhalla, R., Pelus, L., Nathan, C.F., Sherwin, S.A., Oettgen, H.F., and Krown, S.E., 1986, Phase I trial of recombinant interferon gamma in cancer patients, J. Clin. Oncol., 4: 137–146.
Van der Burg, M., Edelstein, M., Gerlis, L., Liang, C-M., Hirschi, M., and Dawson, A., 1985, Recombinant interferon-γ (Immuneron): Results of a phase I trial in patients with cancer, J. Biol Response Modifiers, 4: 264–272.
Waldhäusl, W.K. Bratush-Marrain, P.R. Vierhapper, H., and Nowotny, P., 1983, Insulin pharmacokinetics following continuous infusion and bolus injection of regular porcine and human insulin in healthy man. Metabolism, 32: 478–486.
Wills, R.J., Dennis, S., Spiegel, H.E., Gibson, D.M., and Nadler, P.I., 1984, Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection, Clin. Pharmacol. Ther., 35: 722.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Springer Science+Business Media New York
About this chapter
Cite this chapter
Benet, L.Z., Baughman, R.A. (1986). Temporal and Pharmacokinetic Aspects in Delivery of Peptides and Proteins. In: Davis, S.S., Illum, L., Tomlinson, E. (eds) Delivery Systems for Peptide Drugs. NATO ASI Series, vol 125. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9960-6_6
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9960-6_6
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9962-0
Online ISBN: 978-1-4757-9960-6
eBook Packages: Springer Book Archive